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Abstract Membrane type 1-matrix metalloproteinase (MTI- 
MMP) initiates the activation of the zymogen progelatinase M 
72-kDa type IV collagenase by cleavage of the Asn66-Leu 
peptide bond. We previously pointed out that MT1-MMP 
possesses a unique amino acid sequence Arg-Arg-Lys-Arg tn 
which is a potential recognition sequence for furin-like proteases 
(Nature, 370 0994) 61-65). Here, using a recombinant MT1- 
MMP expressed in Escherichia coli we demonstrated that furin 
specifically cleaves MT1-MMP between Argm-Tyr in vitro, 
which resulted in a stimulation of progelatinase A-activation 
function. Tissue inhibitor of metalloproteinases (TIMP)-2 
inhibited activation of progelatinase A by forming a stable 
complex with activated MTI-MMP. 
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1. Introduction 
Membrane type-matrix metalloproteinase (MT-MMP) (re- 
cently renamed membrane type 1-MMP, MT1-MMP) is a new 
member of the matrix metalloproteinase (MMP) family which 
is associated with proteolytic activation of the zymogen pro- 
gelatinase A/72-kDa type IV collagenase A [1-3]. Following 
the first discovery of MT1-MMP, three more MT-MMPs 
(MT2-, MT3-, MT4-MMP) were identified, and these MT- 
MMPs also possess the conserved Arg-Arg-Lys/Arg-Arg se- 
quence sandwiched between the pro- and catalytic domains 
[4-6]. We deduced that this is a recognition sequence for 
Kex2-1ike proteases including furin [1,2]. Stromelysin-3 has a 
similar Arg-Gln-Lys-Arg sequence at the same position, which 
was since shown to be cleaved by furin [7,8]. We recently 
reconstituted progelatinase A processing using a recombinant 
MT1-MMP fusion protein containing the propeptide, catalyt- 
ic and hinge domains, which indicated that MT1-MMP di- 
rectly cleaves Asn66-Leu peptide bond of progelatinase A to 
produce a 64-kDa intermediate form [9]. Here we demonstrate 
that the recombinant MT1-MMP is activated by furin, and 
that tissue inhibitor of MMP (TIMP)-2 makes a stable com- 
plex with the activated MT1-MMP, and thus inhibits proge- 
latinase A-activation function. 
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2. Materials and methods 
2.1. Expression of a recombinant MTI-MMP protein 
A recombinant MT1-MMP protein was expressed asa fusion pro- 
tein with glutathione-S-transferase [9]. The expression plasmid encod- 
ing GST-MT1-MMP (GST-MT) was constructed by inserting an 
MTI-MMP cDNA fragment encoding (Ser 34 to Cys 319) at the EcoRI 
site of the pGENT2 vector [10]. The fusion protein was expressed in
E. coli strain JM109 and purified using glutathione-Sepharose beads 
(Pharmacia Biotech). A purified sample of GST-MT protein absorbed 
on the beads was stored in TNC buffer (100 mM Tris-HCl, pH 7.5, 
150 mM NaCI and 10 mM CaC12) containing 50% glycerol at -70°C. 
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Fig. 1. Cleavage of GST-MT by furin. (A) Structure of GST-MT1- 
MMP fusion protein. (B) Cleavage of GST-MT with furin. GST- 
MT protein absorbed on the glutathione-Sepharose beads was incu- 
bated with furin at the indicated concentrations a  described in Sec- 
tion 2, and then analyzed by SDS-PAGE and Coomasie Brilliant 
Blue staining (panel, C.B.B.). GST-MT treated with furin was sepa- 
rated as above and then analyzed by Western blotting using a 
monoclonal antibody against he catalytic domain of MT1-MMP 
(114-1F2) (panel, Western). 
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2.2. Processing of GST-MT by furin 
Furin truncated at the transmembrane domain was prepared as 
described previously [11,12]. A recombinant MTI-MMP protein ab- 
sorbed on the beads was washed by centrifugation with 100 mM 
HEPES buffer (pH 7.0) containing 1mM CaC12, 0.1% bovine serum 
albumin and then incubated with furin in a same buffer at 37°C for 
1 h. MT1-MMP fragment was identified by Western blotting using a 
monoclonal antibody against the catalytic domain of MT1-MMP 
(114-1F2) [1]. To determine the cleavage site, 5 pg of GST-MT protein 
was incubated with 200 mU/ml of furin, subjected to SDS-polyacryl- 
amide gel electrophoresis (PAGE), and electroblotted onto an Immo- 
bilon-Psq membrane (Millipore). A piece of the membrane containing 
the MT1-MMP fragment band was cut out and applied to a protein 
sequencer (Hewlett Packard, model G1005A system). 
2.3. Interaction between GST-MT and TIMPs 
Recombinant TIMP-1 and TIMP-2 proteins were supplied by K. 
Iwata (Fuji Chemical Industries Ltd., Takaoka, Japan). GST-MT or 
GST protein (20 ng) either treated or untreated with 200 mU/ml furin 
was incubated with about 50 pg of 125I-labeled TIMP-1 or TIMP-2 
for 10 rain at 37°C, and then MT1-MMP protein was immunopreci- 
pitated with anti-MT1-MMP monoclonal antibody (114-1F2) with the 
aid of protein A Sepharose beads. 125I-labeled TIMP-I or TIMP-2 co- 
precipitated with MT1-MMP was separated on 12% SDS-polyacryl- 
amide gel and analyzed with the BAS 1000 scanner. 
3. Results and discussion 
A recombinant MT1-MMP fusion protein GST-MT, which 
contains the propeptide, catalytic and hinge domains of MT1- 
MMP, was incubated with a soluble form of furin for 1 h at 
37°C and then the samples were subjected to SDS-PAGE. As 
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Fig. 3. Effect of inhibitors of MMP. (A) Inhibition of progelatinase 
A processing. Progelatinase A (10 ng) was incubated with 10 ng of 
GST-MT treated with 200 mU/ml furin in the absence (lane, --) or 
presence of 200 ng TIMP-1, TIMP-2 and 10 5 M BB-94 (lanes 
TIMP-1, TIMP-2 and BB-94, respectively) at 37°C for 1 h and ana- 
lyzed by gelatin zymography. (B) Inhibition of progelatinase A 
processing by TIMP-1 or TIMP-2. Progelatinase A (10 rig) was in- 
cubated with 10 ng GST-MT treated with 200 mU/ml furin in the 
presence of various concentrations of TIMP-1 or TIMP-2 and ana- 
lyzed by gelatin zymography. The ratio of processing was deter- 
mined by densitometric analysis. 
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Fig. 2. Activation of MT1-MMP by furin. (A) stimulation of proge- 
latinase A processing by furin. GST-MT recombinant protein (10 
ng) was pre-treated with furin as described in the legend of Fig. 1, 
and then incubated with 10 ng of progelatinase A at 37°C for 1 h, 
which was then analyzed by gelatin zymography. Lane, --: progela- 
tinase A. A culture supernatant from COS-1 cells co-transfected 
with gelatinase A and MT1-MMP plasmids was run as a control 
(lane, MT1-MMP). (B) GST-MT-dependent progelatinase A activa- 
tion. Progelatinase A (10 ng) was incubated with the indicated con- 
centrations of GST-MT treated with 200 mU/ml furin at 37°C for 
1 h and analyzed by gelatin zymography (left panel). Progelatinase 
A (10 ng) was incubated with 5 ng of furin-treated GST-MT for the 
indicated periods and analyzed by gelatin zymography (right panel). 
shown in Fig. 1, incubation of GST-MT with furin resulted in 
cleavage of the 61-kDa protein into 39-kDa and 22-kDa frag- 
ments in a dose-dependent manner. Western blotting with a 
monoclonal antibody against catalytic domain of MT1-MMP, 
114-1F2 indicated that the resultant 22-kDa fragment con- 
tains the catalytic domain. To locate the cleavage site for 
furin, the 22-kDa fragment was excised from the slot, and 
the amino-terminal amino acid sequence was determined. 
The resulting sequence, Tyr-Ala-Ile-Gln-Gly corresponded 
with residues 112-116 of MT1-MMP,  indicating that furin 
cleaves MT I -MMP between Arg 111 and Tyr H2, and thus re- 
moved the prodomain. 
To examine whether the cleavage of MT1-MMP between 
Arg m and Tyr 1~2 facilitates enzymatic activation, progelati- 
nase A-activating capacity was compared between furin-treat- 
ed and untreated GST-MT. Treatment of the recombinant 
protein with furin enhanced progelatinase A-activation cap- 
ability in parallel with the cleavage of prodomain (Fig. 2A). 
Incubation with furin-treated GST-MT processed progelati- 
nase A depending on the concentration of GST-MT (Fig. 
2B). The time course of progelatinase A activation by furin- 
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Fig. 4. Interaction between activated MT1-MMP and TIMPs. GST- 
MT or GST protein treated (lanes, +) or untreated (lanes, - )  with 
furin was incubated with 125I-labeled TIMP-1 (panel, TIMP1) or 
TIMP-2 (panel, TIMP-2), and then MT1-MMP protein was immu- 
noprecipitated using an anti-MT1-MMP monoclonal antibody (114- 
1F2) with the aid of protein A sepharose beads. 125I-labeled TIMP- 
1 or TIMP-2 co-precipitated with MT1-MMP was separated on 
12% SDS-polyacrylamide g l and analyzed by BAS 1000 gel scan- 
ner. 
treated GST-MT is also shown, where incubation of progela- 
tinase A with activated MT1-MMP at a molar ratio of 2 to 1 
caused complete processing within 1 h at 37°C. 
To characterize the activated MT1-MMP, we examined the 
effects of known inhibitors of matrix metalloproteinases, 
TIMP-1, TIMP-2 and BB-94 on the activation of progelati- 
nase A. As shown in Fig. 3, TIMP-2 effectively inhibited 
processing of progelatinase A by furin-treated GST-MT; 
however, TIMP-1 had only a slight effect. BB-94, a general 
inhibitor of MMP also inhibited processing by furin-activated 
GST-MT. These results were essentially same as that achieved 
with untreated GST-MT [9]. A direct interaction of MT1- 
MMP with TIMPs was examined using lZSI-labeled TIMP-1 
and TIMP-2 (Fig. 4). 125I-labeled TIMP-2 was co-precipitated 
with furin-treated, but not with untreated, GST-MT using a 
monoclonal antibody against MT1-MMP. However, TIMP-1 
did not show a detectable interaction with either furin-treated 
or untreated GST-MT. TIMP-2-specific inhibition of progela- 
tinase A processing by GST-MT is consistent with that ob- 
served using a membrane fraction containing activated MT1- 
MMP [13]. Thus, inhibition by TIMP-2 is due to a specific 
binding of TIMP-2 to activated MT1-MMP. We did not ob- 
serve any stimulatory effect of low doses of TIMP-2 on pro- 
gelatinase A processing in a reconstituted soluble system [14]. 
For cell surface activation, processing of progelatinase A must 
be preceeded by binding to the cell surface [15]. TIMP-2 may 
serve as a part of a progelatinase A receptor, collaborating 
with MT1-MMP to recruite progelatinase A to the cell sur- 
face, and this may accelerate the interaction between MT1- 
MMP and progelatinase A. Indeed, the carboxyl fragment of 
progelatinase A, through which TIMP-2 may bind, is essential 
for the binding and processing on the cell surface [13,14,16]. 
However, in a reconstituted soluble system MT1-MMP would 
directly interact with progelatinase A and thus even a trun- 
cated progelatinase A mutant lacking the carboxyl fragment 
was processed by the recombinant form of MT1-MMP (un- 
published ata). 
Recently several mammalian Kex2-1ike proteases have been 
identified besides furin, and it remains to be seen whether 
these Kex2-1ike enzymes also process MT1-MMP [17-22]. 
However, most of these proteases are expresssed in specific 
cells, whereas furin is expressed in a wide variety of cells 
[23,24]. MT1-MMP is expressed in tumor cell lines, endothe- 
lial cells and normal fibroblast cells in the processed form 
([14], unpublished ata). Furin, with its wide distribution, 
may be responsible for this constitutive activation of MT1- 
MMP. Strongin et al. isolated an MT1-MMP-TIMP-2 com- 
plex from HT1080 cells and demonstrated an amino terminus 
at Tyr n2 [14]. However, when we purified a form of MT1- 
MMP truncated at carboxyl transmembrane domain from the 
culture supernatant of CHO cells stably transfected with the 
expression plasmid, we found an amino terminus at Ala u:~ 
[25]. Mutation of Arg-Arg-Lys-Arg m sequence of truncated 
MT1-MMP abolished processing in CHO cells, indicating the 
recognition of this sequence for the processing in cells. It still 
remains to be clarified whether an amino acid Tyr u2 is re- 
moved after cleavage by furin or a protease other than furin 
cleaves MT1-MMP between Tyr u2 and Ala n3 in CHO cells. 
During the course of our study, Pei and Weiss reported 
activation of MT1-MMP using a mutant protein lacking the 
transmembrane domain purified from MDCK cells [26]. Thus 
the same conclusion was drawn from independent experiments 
using different MT1-MMP samples. 
The reconstituted system will be usefull not only for study- 
ing further the characteristics of MT1-MMP, but also for 
screening enzymes involved in the activation of MT1-MMP. 
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